ClinicalTrials.gg
Not yet recruitingNCT07553494Updated Apr 28, 2026

SLN12140 in Adult Participants With IgA Nephropathy in China

A Phase 2 interventional study of SLN12140 and Placebo in IgA Nephropathy (IgAN), sponsored by Linno Pharmaceuticals, Inc.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Linno Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
68th of 109
48 · median 84
Started
2026
with 24 others
Phase 2
27 of 127
14 open now
Primary completion
2027-12
later than 40 of 72 live
Registered
111th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 68th largest by planned enrollment of the 109 interventional ones that give a count, is one of 25 that started in 2026, is one of 27 in phase 2, reaches primary completion later than 40 of the 72 other live ones, and was the 111th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, parallel, double-blind, placebo-controlled, subcutaneous administration Phase II dose-exploration clinical trial aimed at evaluating the efficacy, safety, PK, PD, and immunogenicity characteristics of SLN12140 at different doses in IgA nephropathy subjects who have previously received standard treatment (the standard treatment drugs allowed in this study include: angiotensin-converting enzyme inhibitors [ACEi], angiotensin II receptor blockers [ARB], and sodium-glucose co-transporter 2 inhibitors [SGLT2i]) but have poor control.

The study is divided into four stages, including a screening period of up to 8 weeks, an introduction period of up to 12 weeks, a 40-week double-blind period (including a 36-week treatment period and a 4-week safety follow-up period; all subjects in the three dose groups who are willing to continue treatment and are judged by the investigator to potentially benefit from subsequent treatment will enter the open-label extension period for continued treatment after completing the double-blind period), and a 56-week open-label extension period (all subjects in the three dose groups who are willing to continue treatment and are judged by the investigator to potentially benefit from subsequent treatment will continue SLN12140 at the same dose group [the optimal dose], including a 52-week open treatment period and a 4-week safety follow-up period).

03

Conditions studied

  • IgA Nephropathy (IgAN)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has fully understood the purpose, nature, methods and potential adverse reactions of this trial, volunteers to participate as a subject, is able to communicate effectively with the investigators, understands and complies with all requirements of this study, and voluntarily signs the Form (ICF) prior to initiation of any study procedures.
  • Male and female subjects aged 18 to 80 years (inclusive) at the time of signing the ICF, with body weight ≥ 50 kg for males and ≥ 45 kg for females; (BMI) 18.0-35.0 kg/m² (inclusive).
  • Patients with IgA nephropathy confirmed by within the past 3 years before screening, with renal tubulointerstitial fibrosis \< 50%.
  • Estimated (eGFR) ≥ 30 mL/min/1.73 m² during the screening period, calculated using the 2021 creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
  • During the screening period, 24-hour urine protein-to-creatinine ratio (24h UPCR) ≥ 1.0 g/g; after completion of the run-in period, UPCR ≥ 0.75 g/g or urine protein excretion (UPE) ≥ 0.75 g/day.
  • Must have received standard of care therapy for at least 12 weeks (and at a stable dose for at least 4 weeks) prior to the first dose of study medication, and agree to maintain stable dosing throughout the study period. (Note: Permitted standard of care medications in this study include ACEi/ARB and SGLT2i.)
  • Males and women of (WOCBP; as defined by the Clinical Trials Facilitation and Coordination Group [CTFG] 2020) must agree to follow the guidelines specified in the protocol from the screening period until 6 months after the last dose of study medication.
  • The subject is willing to receive quadrivalent meningococcal vaccine and pneumococcal vaccine at least 14 days before dosing (for subjects vaccinated within 14 days before dosing, antibiotic prophylaxis for at least 14 days is required after the first vaccination). Re-vaccination is not required for those who have received quadrivalent meningococcal vaccine within 3 years before the first dose, or pneumococcal vaccine within 5 years before the first dose.

Exclusion criteria

Exclusion Criteria:

  • A known history of , allergy, or anaphylactic reaction to any component of the product, including hypersensitivity to human, humanized, or murine monoclonal antibodies, or known hypersensitivity to any ingredient of the product.
  • Secondary IgA nephropathy as determined by the investigator, such as that caused by Henoch-Schönlein purpura, systemic lupus erythematosus, hepatitis, ankylosing spondylitis, infection, or other etiologies.
  • Diagnosis of IgA vasculitis.
  • Current presence or history of nephrotic syndrome.
  • Clinical suspicion of IgA nephropathy with rapidly progressive glomerulonephritis in accordance with the Kidney Disease: Improving Global Outcomes (KDIGO) 2025 guidelines (≥50% decline in within 3 months prior to ICF signature, or a \<50% decline but at risk of rapid renal function deterioration as assessed by the investigator).
  • Clinical suspicion or -confirmed chronic kidney disease caused by any disease other than IgA nephropathy, including other glomerulopathies or podocytopathies.

Other protocol-defined exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    SLN12140

    SLN12140 by subcutaneous (sc) injection:100mg QW; SLN12140 by subcutaneous (sc) injection:200mg QW; SLN12140 by subcutaneous (sc) injection:600mg Q4W;

    Drug: SLN12140

  • Placebo comparator
    Placebo

    Placebo (0.9% sodium chloride solution) will be provided as an injectable solution without active ingredient for 36 weeks.

    Other: Placebo

Interventions

  • SLN12140 by subcutaneous (sc) injection:100mg QW for 36 weeks in blind treatment period; SLN12140 by subcutaneous (sc) injection:200mg QW for 36 weeks in blind treatment period; SLN12140 by subcutaneous (sc) injection:600mg Q4W for 36 weeks in blind treatment period; after 36 weeks of blind treatment period, all of subjects will receive SLN12140 treatment for 52 weeks as open-label extension period with one optimal dosage.

  • OtherPlacebo

    Placebo (0.9% sodium chloride solution) will be provided as an injectable solution without active ingredient for 36 weeks in blind treatment period.

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in urine protein-to-creatinine ratio (UPCR)at Week 36

    Change from baseline in Urine protein-to-creatinine ratio (UPCR) by visit.

    Time frame: Week 36

Secondary outcomes

  1. Mean change from baseline in urine protein-to-creatinine ratio (UPCR)at Week 24

    Change from baseline in Urine protein-to-creatinine ratio (UPCR) by visit.

    Time frame: Week 24

  2. Mean change from baseline in urine albumin-to-creatinine ratio (UACR) at Weeks 24, 36;

    Change from baseline in Urine albumin-to-creatinine ratio (UACR) by visit.

    Time frame: Weeks 24, 36

  3. Mean change from baseline in estimated glomerular filtration rate (eGFR) at Weeks 12, 24, 36

    Change from baseline in eGFR by visit

    Time frame: Weeks 12, 24, 36

  4. Mean changes from baseline in 24-hour urinary protein excretion (24h-UPE) at weeks 24 and 36.

    Time frame: Weeks 24 and 36

  5. Mean changes from baseline in 24-hour urinary albumin excretion (24h-UAE) at weeks 24 and 36.

    Time frame: Weeks 24 and 36

  6. Mean changes from baseline in quantitative first morning void (FMV) UPCR at weeks 2, 4, 8, 12, 24, and 36.

    Time frame: Weeks 2, 4, 8, 12, 24, and 36.

  7. Mean changes from baseline in quantitative FMV-UACR at weeks 2, 4, 8, 12, 24, and 36.

    Time frame: Weeks 2, 4, 8, 12, 24, and 36.

  8. Number and severity of treatment-emergent adverse events

    Number and intensity of adverse events

    Time frame: 106 weeks

  9. Incidence of treatment-induced anti-drug antibodies

    Anti-drug antibody (ADA), incidence, titers and duration

    Time frame: Weeks 4、8、12、24、36 and 40

  10. Pharmacokinetics (PK)parameters of SLN12140: Area Under The Plasma Concentration-time Curve

    Time frame: Baseline through week 92 (predose and postdose)

  11. PK: Maximum Plasma Concentration (Cmax)

    To characterize the pharmacokinetics of SLN12140 in participants with IgAN

    Time frame: Baseline through week 92( predose and postdose)

  12. PK: Time To Maximum Concentration (Tmax)

    To characterize the pharmacokinetics of SLN12140 in participants with IgAN

    Time frame: Baseline through week 92( predose and postdose)

  13. Complement Alternative Pathway (AP) Functional Activity

    Serum AP functional activity was measured by the Wieslab functional immunoassay method.

    Time frame: Baseline through week 92( predose and post dose)

  14. Complement FP

    Plasma FP was measured by enzyme-linked immunosorbent assay (ELISA).

    Time frame: Baseline through week 92(predose and postdose)

07

Study locations

1 site
  • Beijing University 1st hospital
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: Undecided — It is not decided yet at this moment if we will share IPD with other researchers, or when will IPD will be shared, or with whom will IPD be shared, or by what mechanism will IPD be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2027, 19 months later.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 28, 2026
StartEst.
May 29, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07553494
Lead sponsor
Linno Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
May 29, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Apr 28, 2026

Study contacts

Jicheng lv, Professor
Contact
jichenglv@bjmu.edu.cn
0086-10-83575603
Hong ZHANG, Professor
principal investigator · Beijing University First Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SLN12140

Start the discussion